Expert panelists review updated data in the identification and management of resectable cutaneous squamous cell carcinoma and reflect on how real-world practice has evolved.
EP. 9: Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
April 12th 2023Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
EP. 10: Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
April 12th 2023A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
EP. 11: CSCC: Translating Cemiplimab Data Into Practice
April 19th 2023Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.